TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+0.51%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.57B
AUM Growth
-$21.5M
(-0.83%)
Cap. Flow
+$30M
Cap. Flow
% of AUM
1.17%
Top 10 Holdings %
Top 10 Hldgs %
39.02%
Holding
198
New
37
Increased
49
Reduced
41
Closed
10
Top Buys
| 1 |
Pfizer
PFE
|
$38.2M |
| 2 |
Johnson & Johnson
JNJ
|
$20.1M |
| 3 |
Esperion Therapeutics
ESPR
|
$13.7M |
| 4 |
Nektar Therapeutics
NKTR
|
$13.2M |
| 5 |
Bristol-Myers Squibb
BMY
|
$11.2M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
$34.4M |
| 2 |
Amgen
AMGN
|
$27.5M |
| 3 |
Biogen
BIIB
|
$18.3M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$17.9M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
$16.9M |
Sector Composition
| 1 | Healthcare | 93.47% |
| 2 | Real Estate | 2.71% |
| 3 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Centene
CNC
$14.2B
| $24.6M | 0.96% |
460,316
| – | – |
|
27
Neurocrine Biosciences
NBIX
$14.3B
| $23.2M | 0.9% |
279,419
-45,648
| -14% | -$3.79M |
|
28
CVS Health
CVS
$93.6B
| $22.8M | 0.89% |
366,521
| – | – |
|
|
29
BioMarin Pharmaceuticals
BMRN
$11.1B
| $22.8M | 0.89% |
281,076
-208,669
| -43% | -$16.9M |
|
30
SPDR S&P Biotech ETF
XBI
$5.39B
| $22M | 0.85% |
250,460
+24,000
| +11% | +$2.11M |
|
31
Elevance Health
ELV
$70.6B
| $20.1M | 0.78% |
91,482
+46,564
| +104% | +$10.2M |
|
|
SAGE
32
DELISTED
Sage Therapeutics
SAGE
| $20.1M | 0.78% |
124,650
+56,835
| +84% | +$9.15M |
|
33
Teva Pharmaceuticals
TEVA
$21.7B
| $18.5M | 0.72% |
1,083,223
-499,885
| -32% | -$8.54M |
|
34
Jazz Pharmaceuticals
JAZZ
$7.86B
| $18.5M | 0.72% |
122,482
+24,061
| +24% | +$3.63M |
|
|
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.1M | 0.71% |
346,499
+122,799
| +55% | +$6.43M |
|
|
SHPG
36
DELISTED
Shire pic
SHPG
| $17.3M | 0.67% |
115,629
-86,110
| -43% | -$12.9M |
|
37
Omega Healthcare
OHI
$12.7B
| $15.7M | 0.61% |
579,785
| – | – |
|
38
Alnylam Pharmaceuticals
ALNY
$59.2B
| $15.5M | 0.6% |
130,376
+15,410
| +13% | +$1.84M |
|
39
AstraZeneca
AZN
$253B
| $15.5M | 0.6% |
442,600
| – | – |
|
40
GSK
GSK
$81.5B
| $15.4M | 0.6% |
315,799
+28,599
| +10% | +$1.4M |
|
|
PVLA
41
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $14.2M | 0.55% |
26,092
+1,562
| +6% | +$852K |
|
42
McKesson
MCK
$85.5B
| $13.9M | 0.54% |
98,797
-25,153
| -20% | -$3.54M |
|
|
43
Esperion Therapeutics
ESPR
$540M
| $13.7M | 0.53% |
+189,287
| New | +$13.7M |
|
|
44
Nektar Therapeutics
NKTR
$764M
| $13.2M | 0.51% |
+8,301
| New | +$13.2M |
|
45
Amicus Therapeutics
FOLD
$2.46B
| $13.2M | 0.51% |
875,304
+270,384
| +45% | +$4.07M |
|
46
Sabra Healthcare REIT
SBRA
$4.56B
| $12.8M | 0.5% |
724,606
| – | – |
|
47
Boston Scientific
BSX
$159B
| $12.5M | 0.49% |
457,585
+192,985
| +73% | +$5.27M |
|
|
GWPH
48
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $12.5M | 0.49% |
110,784
+85,784
| +343% | +$9.67M |
|
49
Alkermes
ALKS
$4.94B
| $12.2M | 0.47% |
210,182
+66,110
| +46% | +$3.83M |
|
|
BLUE
50
DELISTED
bluebird bio
BLUE
| $11.3M | 0.44% |
5,119
+1,483
| +41% | +$3.28M |
|